Clinical trials Our clinical trials Phase 1b study of BMS-986158 Monotherapy (Myelofibrosis - RECRUITMENT: CLOSED) Project Title A study to assess the safety and tolerability of BMS-986158 alone and in combination with either Ruxolitinib or Fedratinib in participants with blood cancer (Myelofibrosis) Official Title A Phase 1b Study of BMS-986158 Monotherapy and in Combination With Either Ruxolitinib or Fedratinib in Participants With DIPSS-Intermediate or High Risk Myelofibrosis Project Summary The purpose of this study is to assess the safety, tolerability, and efficacy of BMS-986158 alone and in combination with either Ruxolitinib or Fedratinib in participants with Dynamic International Prognostic Scoring System (DIPSS)-intermediate or high risk blood cancer. Part 1 consists of BMS-986158 in combination with either Ruxolitinib or Fedratinib and Part 2 consists of BMS-986158 in combination with either Ruxolitinib or Fedratinib and BMS-986158 alone. Blood Disorder Myelofibrosis Patient Recruitment Details Patient recruitment status: closed Number of Patients (Globally) Undetermined.